OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

SUWON, South Korea–(BUSINESS WIRE)–#7thOPTCongress—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that Behfar Ardehali, Ph.D., Senior Scientist of the Company, presented at the 7th Annual OPT Congress Oligonucleotide & Precision Therapeutics. The OPT Congress is being held both in-person and virtually March 15-16, 2022. At the congress, Dr. Ardehali discussed the potential utility of GalNAc-asiRNA platform for treatment of liver diseases and presented the Company�s latest advancements in liver programs, including Nonalcoholic steatohepatitis (NASH) and HBV.

Details for the presentation are below:

Presentation: Development of a GalNAc-asiRNA Platform for Treatment of Liver Disorders

Date & Time: Tuesday, March 15, 2022 at 11:00 AM EDT

Location: Revere Hotel Boston Common, USA

Event Link: https://www.optcongress.com

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng

Contacts

OliX Pharmaceuticals

Kelly Kim

+82-2-3489-4800

ccnc@olixpharma.com